Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry

Jose-Manuel Ramos-Rincon 1,*, Lidia Cobos-Palacios 2,3, Almudena López-Sampalo 2,3, Michele Ricci 2,3,4, Manuel Rubio-Rivas 5, Francisco Martos-Pérez 5, Antonio Lalueza-Blanco 6, Sergio Moragón-Ledesma 7, Eva-Maria Fonseca-Aizpuru 8, Gema-María García-García 9, Jose-Luis Beato-Perez 10, Claudia Josa-Laorden 11, Francisco Arnalich-Fernández 12, Sonia Molinos-Castro 13, Jose-David Torres-Peña 14,15, Arturo Artero 16, Juan-Antonio Vargas-Núñez 17, Manuel Mendez-Bailon 18, Jose Loureiro-Amigo 19, María-Soledad Hernández-Garrido 20, Jorge Peris-García 21, Ricardo Gómez-Huelgas 2,3,15, and on behalf of the SEMI-COVID-19 Network †

1 Clinical Medicine Department, Miguel Hernandez University of Elche, 03550 Alicante, Spain
2 Internal Medicine Department, Regional University Hospital of Málaga, Biomedical Research Institute of Málaga (IBIMA), 29010 Malaga, Spain; cobospalacios@gmail.com (L.C.-P.); almu_540@hotmail.com (A.L.-S.); michele.ricci@gmail.com (M.R.); ricardogomezhuelgas@hotmail.com (R.G.-H.)
3 Internal Medicine Department, University of Málaga, 29010 Malaga, Spain
4 Department of Internal Medicine, Bellvitge University Hospital, L’Hospitalet de Llobregat, 08907 Barcelona, Spain; mrubio@bellvitgehospital.cat
5 Internal Medicine Department, Costa del Sol Hospital, 29603 Marbella, Spain; pacomartos1@gmail.com
6 Internal Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain; laluze@hotmail.com
7 Internal Medicine Department, Gregorio Marañón General University Hospital, 28007 Madrid, Spain; sergio.moragon@salud.madrid.org
8 Internal Medicine Department, Cabuñas University Hospital, 33394 Gijón, Spain; evamfonseca@yahoo.es
9 Internal Medicine Department, Badajoz University Hospital Complex, 06080 Badajoz, Spain; geminway21@hotmail.com
10 Internal Medicine Department, Albacete University Hospital Complex, 02006 Albacete, Spain; jlbeato@sscam.org
11 Internal Medicine Department, Royo Villanueva Hospital, 50015 Zaragoza, Spain; claudiajosa@gmail.com
12 Internal Medicine Department, La Paz University Hospital, 28046 Madrid, Spain; farnalich@salud.madrid.org
13 Internal Medicine Department, Santiago de Compostela Clinic Hospital, 15706 Santiago de Compostela, Spain; sonia.molinos.castro@sergas.es
14 Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain; h42topej@uco.es
15 Spain CIBER Fisiopatología de la Obesidad y la Nutrición, Carlos III Health Institute, 28029 Madrid, Spain
16 Internal Medicine Department, Doctor Peset University Hospital, 46017 Valencia, Spain; arturo.artero@uv.es
17 Internal Medicine Department, Puerta de Hierro University Hospital, Instituto de Investigación Sanitaria Puerta de Hierro—Segovia de Arana, 28222 Madrid, Spain; juanantonio.vargas@uam.es
18 Internal Medicine Department, San Carlos Clinico Hospital, 28040 Madrid, Spain; manuelmenba@hotmail.com
19 Internal Medicine Department, Moisés Broggi Hospital, 08970 Sant Joan Despí, Spain; jose.loureiro.amigo@gmail.com
20 Internal Medicine Department, Elda General University Hospital, 03600 Alicante, Spain; soleilhg@gmail.com
21 Internal Medicine Department, de Sant Joan d’Alacant University Clinic Hospital, 03550 Alicante, Spain; jorgeperisgarcia@gmail.com
22 Internal Medicine Department, Monforte de Lemos Hospital, 27400 Lugo, Spain; manuel.lorenzo.lopez.reboiro@sergas.es
23 Internal Medicine Department, University Hospital Virgen del Rocío, 41013 Sevilla, Spain; boscobar@icloud.com
24 Internal Medicine Department, Infanta Cristina University Hospital, Parla, 28981 Madrid, Spain; jm.casas@gmail.com
* Correspondence: jramosrincon@yahoo.es or jose.ramosr@umh.es; Tel.: +34-965-933-505
† A complete list of the SEMI-COVID-19 Network members is provided in the Appendix A.
Abstract: (1) Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5–58.9) to 57.1 (44.1–67.1) vs. 71.5 (59.5–81.4) years, \( p < 0.001 \)). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10–0.79), \( p = 0.017 \)) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17–1.60), \( p < 0.001 \)) and (OR (95%CI) 1.74 (1.26–2.41), \( p < 0.001 \)). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21–1.71), \( p < 0.001 \)). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often.

Keywords: COVID-19; SARS-CoV-2; ethnic groups; minority groups; migrants; Spain

1. Introduction

There have been over 404 million reported COVID-19 infections and more than 5.7 million deaths worldwide in the COVID-19 pandemic as of 8 February 2022 [1]. In the United States of America, the pandemic has disproportionately affected racial and ethnic minority populations, who are at an increased risk of infection, hospitalization, and death [2–4]. Differences in access to healthcare and exposure risk may be driving higher infection and mortality rates among these groups [2,5,6]. In the UK, clear differences have been found in the risk of COVID-19 hospitalization according to ethnicity [7,8]. However, little evidence is available from other countries on this matter.

Immigration, especially from Latin America, has changed the demographic landscape of Spain over the last two decades. The number of persons living in Spain on 1 January 2021 was 47.40 million, of whom 1.46 million were from Central and South America, 0.81 million were from North Africa, 0.43 million were from Asia, and 0.25 million were from Sub-Saharan Africa [9]. This influx of immigrants into Spain makes it necessary to study whether there are differences in the clinical progress of patients with COVID-19 according to their ethnicity. Few studies have analyzed the effect of ethnicity on patient progress in Spain [10–15] or other European Union countries [16]. Although the Spanish healthcare system is universal and accessibility is theoretically guaranteed to all [17,18], there is little information about ethnicity in health outcomes among patients in Spanish hospitals during the COVID-19 pandemic.

This work analyzes differences according to ethnicity in the adverse outcomes of in-hospital mortality (IHM), admission to the intensive care unit (ICU), the use of invasive mechanical ventilation (IMV), and a composite variable of the three using data from the SEMI-COVID-19 Registry, a large, geographically-diverse surveillance network for COVID-19-associated hospitalizations in 150 Spanish hospitals [19,20].
2. Materials and Methods

2.1. Study Design and Population

This retrospective cohort study analyzed a nationwide, multicenter registry of patients hospitalized with confirmed COVID-19 in Spain from 1 March 2020 to 30 April 2021. The patients were analyzed according to the pandemic wave in which they were admitted during the study period: the first wave or the second wave. The first wave included patients admitted from 1 March to 30 June 2020 and the second wave included patients admitted from 1 July 2020 to 31 January 2021.

2.2. Definition of Variables

All patient data were obtained from the Spanish Society of Internal Medicine’s SEMI-COVID-19 Registry, in which 150 Spanish hospitals participate. The SEMI-COVID-19 Registry prospectively compiles data on the index admission of patients ≥18 years of age with COVID-19 confirmed microbiologically through a reverse transcription polymerase chain reaction (RT-PCR) or antigen test. More in-depth information about the justification, objectives, methodology, and preliminary results of the SEMI-COVID-19 Registry have recently been published [19,20].

The data on ethnicity were determined based on the place of birth indicated on the patient’s electronic medical record (EMR). For this analysis, ethnicity was categorized as follows:

1. Latin Americans: individuals born in Central and South America
2. Asian: individuals born in Asia
3. Sub-Saharan Africans: individuals born in Sub-Saharan Africa
4. North Africans: individuals born in North African or Middle Eastern countries excluding Israel
5. European: individuals born in Europe and North America.

The degree of dependence was evaluated using the Barthel Index. Comorbidities were evaluated by means of the age-adjusted Charlson Comorbidity Index (CCI) [21]. Patients were classified as having dyslipidemia, diabetes mellitus, or hypertension if they had a previous diagnosis on their EMR or received pharmacological treatment for these conditions. Atherosclerotic cardiovascular disease was defined as a medical history of coronary heart disease (myocardial infarction, acute coronary syndrome, angina, or coronary revascularization), cerebrovascular disease (stroke, transient ischemic attack), or peripheral arterial disease (intermittent claudication, revascularization, lower limb amputation, or abdominal aortic aneurysm). Chronic pulmonary disease was defined as diagnosis of asthma and/or chronic obstructive pulmonary disease. Malignancy encompassed hematologic neoplasia and/or solid tumors (excluding non-melanoma skin cancer). All baseline comorbidities were gathered from EMR obtained from the hospitals.

The endpoints of the study were 30-day all-cause IHM; admission to the ICU; use of IMV; and a composite variable of IHM, admission to the ICU, and use of IMV.

2.3. Statistical Analysis

Each group’s characteristics were analyzed using descriptive statistics. Continuous and categorical variables were expressed as medians and interquartile ranges (IQR) and as absolute values and percentages, respectively. The differences between groups were analyzed using the Mann–Whitney U test and Kruskal–Wallis test for continuous variables, and Pearson’s chi-square test for categorical variables. Statistical significance was defined as \( p < 0.05 \).

Differences in IHM, ICU admission, use of IMV, and composite outcome were adjusted by age (0–44, 45–64, or 65+ years), sex, COVID-19 wave, nosocomial acquisition, and baseline CCI category (0–2, 3–4, 5+) using a multivariable regression analysis and a stepwise regression with a threshold of \( p < 0.10 \). These data are shown in Supplementary Tables S1–S4. The values are expressed as adjusted odds ratios (OR) with 95% confidence intervals (CI). Statistical analyses were performed using IBM SPSS Statistics v25 (Armonk, NY, USA).
2.4. Ethical Aspects

This work was approved by the Institutional Research Ethics Committee of Málaga on 27 March 2020 (Ethics Committee code: SEMI-COVID-19 27-03-20), as per the guidelines of the Spanish Agency of Medicines and Medical Products. All patients gave informed consent. All data collected, processed, and analyzed in this work were anonymized and used only for the purposes of this project. All data were protected in accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data. This study was approved by the Institutional Research Ethics Committees of each participating hospital. The STROBE statement guidelines were adhered to in the execution and reporting of the study.

3. Results

3.1. Study Sample

Of the 23,254 hospitalized patients included in the SEMI-COVID-19 Registry, data on ethnicity were not available for 301. Therefore, the total population analyzed included 23,953 patients (median age 69.5 years, 42.9% women). Of them, 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European (Table 1). The patients in the ethnic minority groups were significantly younger than European patients (median (IQR) age range 49.1 (40.5–58.9) to 57.1 (44.1–67.1) years vs. 71.5 (59.5–81.4) years, \( p < 0.001 \) for all pairwise comparisons of ethnic minority groups vs. European patients). There were significantly more women in the Latin American group (46.1%) and significantly fewer women in the Sub-Saharan African (38.7%), Asian (33.6%), and North African (33.6%) groups than in the European group (42.3%) (\( p < 0.001 \)).

Most of the patients were admitted in the first wave (73.5%); there were significantly fewer patients from the first wave in the North African (58.0%) and Sub-Saharan African (58.9%) than the Asian (69.1%), European (73.8%), and Latin American (74.8%) groups (\( p < 0.001 \)). The patients in ethnic minority groups had significantly fewer comorbidities as assessed by CCI than European patients (median (IQR) range 1 (0–2) to 2 (0–3.0) vs. 4 (2–5) European patients, \( p < 0.001 \)) (Table 1). In general, the ethnic minority groups had lower rates of hypertension, dyslipidemia, non-atherosclerotic heart disease, atherosclerotic cardiovascular disease, diabetes mellitus, malignancy, dementia, and kidney disease than the European patients (Table 1).

3.2. Study Outcomes

3.2.1. In-Hospital Mortality

The unadjusted proportion of deaths during hospitalization differed across the ethnic groups, with higher IHM observed among European patients (21.6%) and lower IHM observed among Sub-Saharan African (3.2%), Latin American (7.1%), Asian (10.9%) and North African patients (11.4%) (Table 2; overall \( p < 0.001 \)). After adjusting for demographic differences and CCI, Sub-Saharan African patients were 70% less likely to die during hospitalization than European patients (OR (95% CI) 0.28 (0.10–0.79), \( p = 0.017 \)). The differences observed between the other ethnic minority groups compared to European patients were not statistically significant (Table 3, \( p > 0.05 \) for all). The results of IHM during the first wave and second wave data are shown in Supplementary Tables S5 and S6.
Table 1. Demographic and clinical characteristics of patients with confirmed COVID-19 by ethnic group.

| M | Total (n = 22,953) | Latin Americans (n = 1839; 8.0%) | North Africans (n = 281; 1.2%) | Sub-Saharan Africans (n = 124; 0.5%) | Asians (n = 110; 0.5%) | Europeans (n = 20,599; 89.7%) | Global p | LA vs. E p | NA vs. E p | SS vs. E p | Asian vs. E p |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, years, median (IQR) | 0 | 69.5 (56.7–80.1) | 49.1 (40.5–58.9) | 57.1 (44.1–67.1) | 50.0 (42.3–61.3) | 49.7 (41.1–62.4) | 71.5 (59.5–81.4) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Age, years, n (% | 18–39 | 0 | 1340 (5.8) | 433 (23.5) | 46 (16.4) | 23 (18.5) | 23 (20.9) | 815 (4.9) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| | 40–64 | 0 | 8054 (35.1) | 1151 (62.6) | 150 (53.4) | 73 (58.9) | 65 (59.1) | 6617 (32.1) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| | 65+ | 0 | 13,558 (59.1) | 255 (13.9) | 85 (30.2) | 28 (22.6) | 22 (20.0) | 13,168 (63.9) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Sex, female, n (%) | 0 | 9740 (42.4) | 847 (46.1) | 37 (33.6) | 48 (38.7) | 37 (33.6) | 8716 (41.2) | <0.001 | 0.002 | 0.001 | 0.268 |
| Wave, first, n (%) | 0 | 16,879 (73.5) | 1375 (74.8) | 163 (53.4) | 73 (58.9) | 76 (69.1) | 15,192 (73.8) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Nosocomial infection, n (%) | 0 | 1088 (4.7) | 44 (2.4) | 10 (3.6) | 5 (4.0) | 4 (3.6) | 1025 (5.0) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Dependence, mild and severe, n (%) | 218 | 1711 (7.5) | 22 (1.2) | 1 (0.4) | 2 (1.7) | 2 (1.8) | 1684 (8.3) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Baseline CCI, median (IQR) | 0 | 3 (2–5) | 1 (0–2) | 2 (0.0–3.0) | 1 (0–3) | 1.5 (0–2.5) | 4 (2–5) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Baseline CCI, n (%) | 0–2 | 0 | 8595 (38.2) | 1468 (81.5) | 177 (64.4) | 82 (67.8) | 81 (75.0) | 6787 (33.6) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| | 3–4 | 0 | 6328 (28.1) | 208 (81.5) | 60 (21.8) | 25 (20.7) | 16 (14.8) | 6019 (39.8) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| | 5+ | 0 | 7601 (33.7) | 126 (7.0) | 38 (13.8) | 14 (11.6) | 11 (10.2) | 7412 (42.3) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Comorbidities, n (%) | 0 | 11,997 (52.3) | 402 (21.9) | 101 (35.9) | 49 (39.5) | 45 (31.3) | 11,997 (52.3) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Hypertension | 39 | 9091 (39.7) | 389 (21.2) | 89 (31.7) | 30 (24.2) | 25 (22.9) | 8558 (41.6) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Diabetes mellitus | 54 | 3423 (14.9) | 46 (2.5) | 18 (6.4) | 6 (4.8) | 5 (4.6) | 3348 (16.3) | <0.001 | <0.001 | <0.001 | 0.003 |
| Atherosclerotic cardiovascular disease | 81 | 3895 (17.0) | 101 (5.5) | 32 (11.5) | 7 (5.7) | 12 (11.0) | 3743 (18.2) | <0.001 | <0.001 | 0.004 | <0.001 | 0.051 |
| Non-atherosclerotic heart disease | 49 | 4782 (20.9) | 212 (11.6) | 73 (26.0) | 29 (23.8) | 19 (17.4) | 4449 (21.6) | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

a Non-atherosclerotic heart disease includes coronary artery disease, congestive heart failure, and other valvular diseases.

b Atherosclerotic cardiovascular disease includes coronary artery disease, myocardial infarction, and valvular heart disease.
### Table 1. Cont.

|                                | M Total (n = 22,953) | Latin Americans (n = 1839; 8.0%) | North Africans (n = 281; 1.2%) | Sub-Saharan Africans (n = 124; 0.5%) | Asians (n = 110; 0.5%) | Europeans (n = 20,599; 99.7%) | Global p | LA vs. E p | NA vs. E p | SS vs. E p | Asian vs. E p |
|--------------------------------|----------------------|----------------------------------|-----------------------------|-------------------------------------------|-----------------------|--------------------------------|----------|------------|-----------|-----------|---------------|
| Obesity                        | 1806                 | 4775 (22.6)                      | 469 (27.6)                  | 60 (22.4)                                  | 28 (22.8)                     | 10 (9.7)                      | 4208 (22.2) | <0.001     | <0.001    | 0.942     | 0.881         | 0.002         |
| Chronic pulmonary disease c    | 53                   | 3626 (15.8)                      | 175 (9.6)                   | 36 (12.8)                                  | 19 (15.3)                     | 11 (10.1)                     | 3385 (16.5) | <0.001     | <0.001    | 0.100     | 0.732         | 0.073         |
| Malignancy d                   | 33                   | 2290 (10.0)                      | 72 (3.9)                    | 13 (4.6)                                   | 8 (6.5)                        | 7 (6.4)                       | 2190 (10.7) | <0.001     | <0.001    | 0.001     | 0.136         | 0.152         |
| Dementia                       | 39                   | 2777 (9.9)                       | 24 (1.3)                    | 2 (0.7)                                    | 2 (1.6)                       | 1 (0.9)                       | 2248 (10.9) | <0.001     | <0.001    | <0.001    | 0.001         | 0.001         |
| Chronic kidney disease e       | 37                   | 1481 (6.2)                       | 1358 (6.6)                  | 7 (2.5)                                    | 41 (2.2)                      | 5 (4.6)                       | 1358 (6.6) | <0.001     | <0.001    | 0.006     | 0.430         | 0.398         |
| HIV                            | 64                   | 122 (0.5)                        | 23 (1.3)                    | 2 (0.7)                                    | 6 (4.8)                       | 0 (0.0)                       | 91 (0.4)    | <0.001     | <0.001    | 0.499     | <0.001        | 0.486         |
| Obstructive sleep apnea        | 114                  | 1363 (6.0)                       | 51 (2.8)                    | 11 (3.9)                                   | 6 (4.9)                       | 3 (2.8)                       | 11 (3.9)    | <0.001     | <0.001    | 0.106     | 0.530         | 0.128         |
| Chronic liver disease          | 60                   | 808 (3.5)                        | 60 (3.3)                    | 15 (5.4)                                   | 2 (1.6)                       | 8 (7.4)                       | 723 (3.5)   | 0.058      | 0.635     | 0.098     | 0.250         | 0.029         |
|                                |                      |                                  |                             |                                            | Baseline medication use, n (%) |
|                                | ASA                  | 110                              | 3726 (16.3)                 | 78 (4.2)                                   | 33 (11.8)                      | 11 (8.9)                      | 10 (9.3)    | 3594 (17.5) | <0.001    | <0.001    | 0.012         | 0.011         | 0.024         |
|                                | Statin               | 99                               | 7317 (32.0)                 | 248 (13.5)                                 | 20 (18.5)                      | 25 (20.2)                      | 248 (13.5)  | 71 (25.3)   | <0.001    | <0.001    | 0.002         | 0.001         | 0.001         |
|                                | ACE inhibitor        | 88                               | 3998 (17.5)                 | 152 (8.3)                                  | 44 (15.7)                      | 16 (12.9)                      | 18 (16.7)   | 3768 (18.4) | <0.001    | <0.001    | 0.244         | 0.117         | 0.649         |
|                                | ARB                  | 86                               | 4617 (20.2)                 | 148 (8.1)                                  | 31 (11.1)                      | 20 (16.3)                      | 8 (7.4)     | 4410 (21.5) | <0.001    | <0.001    | <0.001        | 0.159         | 0.002         |
|                                | Anticoagulant        | 78                               | 2565 (11.2)                 | 36 (2.0)                                   | 15 (5.4)                       | 6 (4.8)                        | 4 (3.7)     | 2504 (12.2) | <0.001    | <0.001    | <0.001        | 0.012         | 0.007         |

n (%): number of cases (percentage); M: missing value; IQR: interquartile range; CCI: Charlson Comorbidity Index; E: Europeans; LA: Latino-Americans; NA: North Africans; SS: Sub-Saharan. HIV: human immunodeficiency virus. ASA: acetylsalicylic acid. ACE: angiotensin-converting enzyme. ARB: angiotensin receptor blockers. c Non-atherosclerotic heart disease includes atrial fibrillation and/or heart failure. b Atherosclerotic cardiovascular disease includes coronary, cerebrovascular, and/or peripheral vascular disease. d Chronic pulmonary disease includes chronic obstructive pulmonary diseases and/or asthma. e Chronic kidney disease is defined as an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² according to the CKD-EPI equation.

n (%): number of cases (percentage); M: missing value; IQR: interquartile range; CCI: Charlson Comorbidity Index; E: Europeans; LA: Latino-Americans; NA: North Africans; SS: Sub-Saharan. HIV: human immunodeficiency virus. ASA: acetylsalicylic acid. ACE: angiotensin-converting enzyme. ARB: angiotensin receptor blockers. c Non-atherosclerotic heart disease includes atrial fibrillation and/or heart failure. b Atherosclerotic cardiovascular disease includes coronary, cerebrovascular, and/or peripheral vascular disease. d Chronic pulmonary disease includes chronic obstructive pulmonary diseases and/or asthma. e Chronic kidney disease is defined as an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² according to the CKD-EPI equation.
|                      | Total (n = 22,953) | Latin Americans (n = 1839; 8.0%) | North Africans (n = 281; 1.2%) | Sub-Saharan Africans (n = 124; 0.5%) | Asians (n = 110; 0.5%) | Europeans (n = 20,599; 89.7%) | Global p  | LA vs. E p  | NA vs. E p  | SS vs. E p  | Asian vs. E p |
|----------------------|-------------------|---------------------------------|-------------------------------|-------------------------------------|-----------------------|-----------------------------|-----------|-------------|-------------|-------------|---------------|
| **Main outcomes, n (%)** |                   |                                 |                               |                                     |                       |                             |           |             |             |             |               |
| In-hospital mortality | 0                 | 4636 (20.2)                    | 130 (7.1)                     | 32 (11.4)                           | 4 (3.2)               | 12 (10.9)                   | 4458 (21.6)| <0.001      | <0.001      | <0.001      | <0.001        |
| Intensive care unit admission | 11               | 2186 (9.5)                    | 239 (13.0)                    | 47 (16.8)                           | 13 (10.3)             | 16 (14.5)                   | 1871 (9.1)| <0.001      | <0.001      | <0.001      | 0.590         |
| Invasive mechanical ventilation | 92          | 1664 (7.3)                    | 185 (10.1)                    | 30 (10.8)                           | 9 (7.3)               | 10 (9.1)                    | 1430 (7.0)| <0.001      | <0.001      | 0.014       | 0.880         |
| Composite outcome    | 57                | 5983 (26.1)                   | 289 (15.8)                    | 61 (21.9)                           | 17 (13.8)             | 24 (21.8)                   | 5592 (27.2)| <0.001      | 0.001       | 0.050       | 0.001         |
| **Other outcomes, n (%)** |                   |                                 |                               |                                     |                       |                             |           |             |             |             |               |
| Non-invasive mechanical ventilation | 100          | 1325 (5.8)                    | 113 (6.2)                     | 24 (8.6)                            | 9 (7.3)               | 7 (6.4)                     | 1172 (5.7)| 0.255       | 0.421       | 0.040       | 0.443         |
| High-flow oxygen therapy | 158             | 2199 (9.6)                    | 215 (11.8)                    | 45 (16.2)                           | 16 (13)               | 11 (10.0)                   | 1912 (9.3)| <0.001      | 0.001       | <0.001      | 0.164         |
| Length of hospital stay, days, median (IQR) | 145          | 9 (5–14)                      | 8 (5–13)                      | 9 (6–15)                            | 9 (6–15)              | 8 (5–16)                    | 9 (6–14) | 0.023       | 0.027       | 0.104       | 0.297         |
| Length of hospital stay >10 days, n (%) | 145           | 10,276 (45.1)                 | 762 (41.5)                    | 137 (49.3)                          | 61 (49.5)             | 48 (43.6)                   | 9268 (45.3)| 0.012       | 0.002       | 0.186       | 0.341         |

φ All patients; M: missing value; E: Europeans; LA: Latin Americans; NA: North Africans; SS: Sub-Saharan Africans; IQR: Interquartile range.
Table 3. Crude and multivariable logistic regression model for mortality, intensive care unit admission, and invasive mechanical ventilation among patients with confirmed COVID-19 by ethnicity.

| Independent Variables          | Crude Odds Ratio (95% CI) | p    | Adjusted Model \(^a\) Odds Ratio (95% CI) | p    |
|-------------------------------|--------------------------|------|------------------------------------------|------|
| **In-hospital mortality**     |                          |      |                                          |      |
| Latin Americans               | 0.27 (0.23–0.33)         | <0.001 | 1.11 (0.90–1.36)                         | 0.320|
| North Africans                | 0.46 (0.32–0.67)         | <0.001 | 1.05 (0.70–1.60)                         | 0.786|
| Sub-Saharan Africans          | 0.12 (0.04–0.32)         | <0.001 | 0.28 (0.10–0.79)                         | 0.017|
| Asians                        | 0.44 (0.24–0.80)         | 0.008 | 1.50 (0.77–2.93)                         | 0.320|
| Europeans                     | Ref                      |      | Ref                                      |      |
| **Intensive care unit admission** |                        |      |                                          |      |
| Latin Americans               | 1.49 (1.29–1.72)         | <0.001 | 1.37 (1.17–1.60)                         | <0.001|
| North Africans                | 2.01 (1.47–2.71)         | <0.001 | 1.74 (1.26–2.41)                         | 0.001|
| Sub-Saharan Africans          | 1.17 (0.65–2.08)         | 0.590 | 1.03 (0.57–1.86)                         | 0.903|
| Asians                        | 1.70 (1.00–2.90)         | 0.050 | 1.49 (0.87–2.56)                         | 0.145|
| Europeans                     | Ref                      |      | Ref                                      |      |
| **Invasive mechanical ventilation** |                        |      |                                          |      |
| Latin Americans               | 1.50 (1.27–1.76)         | <0.001 | 1.43 (1.21–1.71)                         | <0.001|
| North Africans                | 1.60 (1.10–2.36)         | 0.015 | 1.50 (1.01–2.21)                         | 0.051|
| Sub-Saharan Africans          | 1.05 (0.53–2.08)         | 0.880 | 1.01 (0.50–2.01)                         | 0.974|
| Asians                        | 1.33 (0.68–2.56)         | 1.335 | 1.23 (0.63–2.38)                         | 0.534|
| Europeans                     | Ref                      |      | Ref                                      |      |
| **Composite outcome**         |                          |      |                                          |      |
| Latin Americans               | 0.50 (0.44–0.57)         | <0.001 | 1.13 (0.98–1.31)                         | 0.082|
| North Africans                | 0.79 (0.57–1.00)         | 0.051 | 1.27 (0.93–1.72)                         | 0.122|
| Sub-Saharan Africans          | 0.43 (0.26–0.71)         | 0.001 | 0.79 (0.46–1.35)                         | 0.398|
| Asians                        | 0.75 (0.47–1.17)         | 0.207 | 1.52 (0.94–2.44)                         | 0.085|
| Europeans                     | Ref                      |      | Ref                                      |      |

*Ref.: reference. \(^a\) Adjusted for age group, sex, wave, place of acquisition, and baseline Charlson Comorbidity Index group. See Supplementary Tables S1–S4 for full models.*

3.2.2. Admission to the ICU

The unadjusted proportion of patients admitted to the ICU differed across ethnic groups, with higher ICU admission rates observed among North African (16.8%), Asian (14.5%), and Latin American patients (10.3%), and lower ICU admission rates observed among Sub-Saharan African (10.3%) and European patients (9.1%) (Table 2; global \( p < 0.001 \)). After adjusting for demographic differences and baseline clinical characteristics, Latin American and North African patients were 37% and 74% more likely to be admitted to the ICU than European patients (OR (95% CI) 1.37 (1.17–1.60), \( p < 0.001 \), and OR (95% CI) 1.74 (1.26–2.41), \( p = 0.001 \)) (Table 3), while the differences between Sub-Saharan African and Asian patients compared to European patients were not statistically significant (Table 3, \( p > 0.05 \) for both). The results of admission to the ICU during the first wave and second wave data are shown in Supplementary Tables S5 and S6.
3.2.3. IMV

The unadjusted proportion of need for IMV differed across ethnic groups, with greater use of IMV observed among North African (10.8%) and Latin American (10.1%) patients and less use of IMV among European (7.0%), Sub-Saharan African (7.3%), and Asian (9.1%) patients ($p < 0.001$). After adjusting for demographic differences, Latin American patients were 43% more likely than European patients to use IMV (OR (95% CI) 1.43 (1.21–1.71), $p < 0.001$) (Table 3), while the differences between North African, Sub-Saharan African, and Asian patients compared to European patients were not statistically significant (Table 3, $p > 0.05$ for all). The results of IMV during the first wave and second wave data are shown in Supplementary Tables S5 and S6.

3.2.4. Composite Outcome

The unadjusted proportion of the composite outcome differed across ethnic groups. It was less common among Latin American (15.8%) and Sub-Saharan African (13.8%) patients and more common among European (27.2%), North African (21.9%), and Asian (21.8%) patients ($p < 0.001$). However, there were no differences among ethnic groups after adjusting for demographic differences (Table 3). The results of the composite outcome during the first wave and second wave data are shown in Supplementary Tables S5 and S6.

3.2.5. Other Outcomes

The median length of hospital stay for the total population was 9 days (IQR: 5–14), with significant differences among the ethnic groups (Table 2, total $p = 0.032$). The median length of hospital stay among Latin Americans was significantly shorter than among Europeans (8 days (5–13) vs. 9 days (6–14); $p = 0.024$). The results of other outcomes during all periods of study, and the first wave and second wave data, are shown in Table 2 and Supplementary Tables S5 and S6.

4. Discussion

The main finding of this study is that the ethnicity of patients hospitalized with COVID-19 in Spain was not a determining factor of mortality. In this large, nationwide, retrospective study of nearly 24,000 patients hospitalized in Spain with confirmed COVID-19, around 10% of the patients were ethnic minorities, with Latin Americans being the predominant group. These epidemiological data are similar to other Spanish series of patients with COVID-19 [10–15,17].

As was expected, patients belonging to an ethnic minority group were significantly younger and had fewer comorbidities than the European patients, the group that includes the native Spanish population. This is likely due to the fact that most migrants are of working age and have settled in Spain in the last two decades [22,23].

This study also found that members of ethnic minority groups also had lower non-adjusted rates of mortality and adverse clinical outcomes than European patients. The more favorable COVID-19 outcomes observed in migrants could be justified by the fact that they are a younger, healthier population and it is well known that older age and comorbidities are among the most important risk factors for COVID-19-related complications and mortality [19,22]. However, even after adjusting for age and comorbidities, patients who belonged to ethnic minority groups were found not to have worse outcomes than European patients. These results are different to previous studies in populations in the USA [3–5,7,24–26] and the UK [27], where the racial and ethnic minority groups experienced disproportionately severe COVID-19-associated outcomes. A systematic review that analyzed ethnic disparities in COVID-19 in the USA concluded that African American/Black and Hispanic populations had higher rates of COVID-19-related mortality, but similar case fatality rates [2]. In another systematic review that included 52 studies (75.0% from the USA, 18.1% from the UK, and 6.9% from Brazil), the COVID-19 mortality rate was significantly higher among Blacks and Hispanics compared to Whites [28].
It has been hypothesized that this worse COVID-19 prognosis observed in ethnic minority populations is likely multifactorial [3]. First, some comorbidities such as hypertension, obesity, and chronic kidney disease, which are linked to worse clinical outcomes in COVID-19, are more prevalent in these populations [4,5,29–31]. Second, the differences in immune response and angiotensin-converting enzyme 2 expression and/or polymorphism observed among individuals of different ethnicities [32,33], as well as genetic variations that may lead to greater disease severity among individuals of certain ethnicities, have been proposed [34–36]. Finally, and probably most importantly, social vulnerability and social determinants of health (poverty, low education, and economic levels) are related to an increased risk of both infection and fatality in COVID-19 [37–39]. Additionally, inequities in access to healthcare must be considered as an underlying factor of the poor health outcomes observed [3].

The effect of different healthcare system models on clinical outcomes in COVID-19 has not been well studied. Spain has been ranked among the top countries in the world in regard to healthcare access and quality [40]. Spain’s universal public healthcare system guarantees equal access to all, including immigrants, regardless of their legal status [18,41]. Our results suggest that this universal public healthcare system was critical in minimizing the social determinants of health, palliating the socioeconomic inequalities and lack of access to healthcare that have been linked to ethnic disparities in rates of severe COVID-19 described in other countries [3,29].

The impact of COVID-19 on ethnic minority groups in Spain has been analyzed in a few previous studies. In a population-based study of a cohort of adult patients with PCR-confirmed COVID-19 conducted in Madrid, migrants from Sub-Saharan Africa and Latin America showed an increased risk for COVID-19 compared to Spaniards [11]. This higher risk of COVID-19 among minorities have been widely reported in other countries [2,28] and can likely be explained by socioeconomic determinants of health, as discussed previously.

Regarding the clinical outcomes of COVID-19 in immigrant populations in Spain, the results are not consistent. Several small and/or single-center studies have shown an increased risk of ICU admission and IHM in individuals born in Latin American countries, but the model was not adjusted for comorbidities in these studies [10,12,13]. In another multicenter study from 18 Spanish hospitals that included 10,100 patients hospitalized for COVID-19 during the first wave of infections, 14.8% of whom were not born in Spain, Latin American patients also had higher rates of ICU admission and IHM, but, yet again, no adjustment for comorbidities or clinical and treatment variables was performed [15]. In contrast, a single-center study conducted during the first wave of the pandemic in Madrid found a lower rate of IHM among migrants (73.5% from Latin American countries) after adjusting for comorbidities. Finally, findings similar to our study were reported in a multicenter study in four hospitals in Madrid and Barcelona, which included 5235 patients hospitalized with COVID-19 during the first wave. In that work, Latin American patients had a higher rate of ICU admission, but the IHM rate was not higher; however, comorbidities were not included in the multivariable analysis [14].

Interestingly, the Sub-Saharan African patients in our series showed a lower adjusted mortality rate than other ethnic groups. This good prognosis observed among Sub-Saharan Africans could have several hypothetical explanations. On the one hand, Black Africans, who are assumed to form the majority of the Sub-Saharan African group, have been found to be less likely to carry a gene cluster on chromosome 3 that has been associated with severe COVID-19 [36]. On the other hand, Black patients have also been found to have a lower proportion of abdominal adiposity than Latin American and White patients, and visceral fat has been related to a worse prognosis in COVID-19 [42].

Latin American and North African patients had higher adjusted rates of ICU admission with no associated increase in IHM in our study. The increased frequency of ICU admission in non-European patients could be a result of the younger age of this population, as well as the shortage of resources during the peak of the pandemic’s first wave, which is the period when most patients were included in this study. On the other hand, the high proportion
of visceral fat and metabolic syndrome in Latin American [42,43] and North African patients could explain their worse outcomes [44]. Further studies investigating potential metabolic, immunological, and genetic markers in patients of different geographical origins are required to understand the determinants of COVID-19 clinical outcomes.

Our study is the largest series of hospitalized patients with COVID-19 in Spain. However, this work has several limitations. First, it has a retrospective cohort register. Second, most of our patients were included during the first wave of the pandemic. Third, there was a relatively low proportion of patients from Sub-Saharan Africa and Asia. Fourth, in Spain, like most European Union Member States, anti-discrimination laws based on the EU Data Protection Directive and Article 21 of the EU Charter do not permit data collection on the basis of racial and ethnic origin [45]. Paradoxically, this policy may limit the generation of evidence that could contribute to reducing disparities among ethnic groups. In our study, a patient’s ethnicity was approximated according to their country of birth. Finally, our conclusions may not be applicable to other settings with different healthcare system models.

5. Conclusions

In Spain, which has a universal public healthcare system, no differences in mortality were observed among minority ethnic groups despite socioeconomic disparities. More well-designed, longitudinal studies are needed to analyze the potential disparities in COVID-19 clinical outcomes among ethnic minority populations in order to identify factors that contribute to them, including the healthcare system model.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11071949/s1, Table S1: Full multivariable logistic regression model for in-hospital mortality; Table S2: Full multivariable logistic regression model for intensive care unit admission; Table S3: Full multivariable logistic regression model for use of invasive mechanical ventilation; Table S4: Full multivariable logistic regression model for use of combined outcome; Table S5: Outcomes of patients with confirmed COVID-19 by ethnic group during first wave; Table S6: Outcomes of patients with confirmed COVID-19 by ethnic group during second wave.

Author Contributions: Conceptualization, J.-M.R.-R. and R.G.-H.; methodology, J.-M.R.-R. and R.G.-H.; software, J.-M.C.-R.; validation, J.-M.R.-R. and R.G.-H.; formal analysis, J.-M.R.-R. and R.G.-H.; investigation, L.C.-P., A.L.-S., M.R., M.R.-R., F.M.-P., A.L.-B., S.M.-L., E.-M.F.-A., G.-M.G.-G., J.-L.B.-P., C.J.-L., F.A.-F., S.M.-C., J.-D.T.-P., A.A., J.-A.V.-N., M.M.-B., J.L.-A., M.-S.H.-G., J.P.-G., M.-L.L.-R., B.B.-F. and J.-M.C.-R.; resources, J.-M.R.-R. and R.G.-H.; data curation, L.C.-P., A.L.-S., M.R., M.R.-R., F.M.-P., A.L.-B., S.M.-L., E.-M.F.-A., G.-M.G.-G., J.-L.B.-P., C.J.-L., F.A.-F., S.M.-C., J.-D.T.-P., A.A., J.-A.V.-N., M.M.-B., J.L.-A., M.-S.H.-G., J.P.-G., M.-L.L.-R., B.B.-F. and J.-M.C.-R.; writing—original draft preparation, J.-M.R.-R. and R.G.-H.; writing—review and editing, J.-M.R.-R. and R.G.-H.; visualization, R.G.-H.; supervision, J.-M.R.-R. and R.G.-H.; project administration, J.-M.C.-R. and R.G.-H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The project was approved by the Institutional Research Ethics Committee of Málaga on 27 March 2020 (Ethics Committee code: SEMI-COVID-19 27-03-20), as per the guidelines of the Spanish Agency of Medicines and Medical Products. All patients gave informed consent.

Informed Consent Statement: Only patients who had previously given consent for their medical records to be used for medical research were included in this registry. Data confidentiality and patient anonymity were always maintained, in accordance with Spanish regulations on observational studies.

Data Availability Statement: J.-M.R.-R. and R.G.-H. have full access to the data and are the guarantors for the data.

Acknowledgments: We gratefully acknowledge all of the investigators who participated in the SEMICOVID-19 Registry.

Conflicts of Interest: The authors declare no conflict of interest.
Appendix A

Complete list of the SEMI-COVID-19 Network members: SEMI-COVID-19 Scientific Committee Members: José Manuel Casas Rojo, José Manuel Ramos Rincón, Carlos Lumberas Bermejo, Jesús Millán Núñez-Cortés, Juan Miguel Antón Santos, Ricardo Gómez Huergas. Members of the SEMI-COVID-19 Group H. Univ. de Bellvitge. L’Hospitalet de Llobregat (Barcelona): Xavier Corbella, Francesc Formiga Pérez, Narcís Homs, Abelardo Montero, Jose María Mora-Luján, Manuel Rubio-Rivas. H. U. 12 de Octubre. Madrid: Paloma Águdo de Blas, Coral Arévalo Cañas, Blanca Ayuso, José Bascanuña Morejón, Samara Campos Escudero, María Carnevali Frías, Santiago Cossio Tejido, Borja de Miguel Campo, Carmen Díaz Pedrero, Raquel Díaz Simon, Ana García Reyne, Laura Ibárra Veganzones, Lucía Jorge Huerta, Antonio Lallegra Blanco, Jaime Laureiro Gonzalo, Jaime Lora-Tamayo, Carlos Lumberas Bermejo, Guillermo Maestro de la Calle, Rodrigo Miranda Godoy, Bárbara Otero Perpiña, Diana PareDES Ruiz, Marcos Sánchez Fernández, Javier Tejada Montes H. Costa del Sol. Marbella (Málaga): Victoria Augustin Bandera, Javier García Alegria, Nicolás Jiménez-García, Jairo Luque del Pino, María Dolores Martín Escalante, Francisco Navarro Romero, Victoria Núñez Rodríguez, Julián Olalla Sierra H. U. Gregorio Marañón. Madrid: Laura Abarca Casas, Álvaro Alejandro de Oña, Rubén Alonso Beato, Leyre Alonso Gonzalo, Jaime Alonso Muñoz, Cristian Mario Amodeo Oblitas, Cristina Áusín García, Marta Bacete Cebríni, Jesús Baltasar Corral, María Barrientos Guerrero, Alejandro D. Bendala Estrada, María Calderón Moreno, Paula Carrascosa Fernández, Raquel Carrillo, Sabela Castañeda Pérez, Eva Cervilla Muñoz, Agustín Diego Chacón Moreno, María Carmen Cuencà Carvajal, Sergio de Santos, Andrés Enriquez Gómez, Eduardo Fernández Carracedo, María Mercedes Ferreiro-Mazón Jenaro, Francisco Galeano Valle, Alejandro García, Irene García Fernandez-Bravo, María Eugenia García León, María Gómez Antúnez, Candela González San Narciso, Anthony Alexander Gurfian, Lorena Jiménez Ibáñez, Cristina Lavilla Olleros, Cristina Llamazares Mendoza, Sara Luis García, Víctor Mato Jimeno, Clara Millán Noales, Jesús Millán Núñez-Cortés, Sergio Moragón Ledesma, Antonio Muñoz Miguez, Cecilia Muñoz Delgado, Lucía Ordieres Ortega, Susana Pardo Sánchez, Alejandro Parra Virto, María Teresa Pérez Sanz, Blanca Pinilla Llorente, Sandra Piqueras Ruiz, Guillermo Sorín Fernández-Llamazares, María Toledano Macías, Neera Toledo Samaniego, Ana Torres de Rego, María Victoria Villalba García, Gracia Villarreal, María Zurita Etayo H. de Cabueñes. Gijón (Asturias): Ana María Álvarez Suárez, Carlos Delgado Vergés, Rosa Fernandez-Fadenera Martínez, Eva Mª Fonseca Aizpuru, Alejandro Gómez Carrasco, Cristina Helguera Amezua, Juan Francisco López Caleya, Diego López Martínez, María del Mar Martínez Lópe, Aleida Martínez Zapico, Carmen Olabuenaga Iscar, Lucía Pérez Casado, María Luisa Taboada Martínez, Lara María Tamargo Chamorro C. H. U. de Albacete Jose Luis Beato Pérez, María Lourdes Sáez Méndez C. H. U. de Badajoz Rafael Aragon Lara, Inmaculada Cimadevilla Fernandez, Juan Carlos Ciar García, Gema María García García, Julia Gonzalez Granados, Beatriz Guerrero Sánchez, Francisco Javier Monreal Periáñez, María Josefa Pascual Perez. H. Royo Villanueva. Zaragoza: Nicolás Alcalá Rivera, Anxela Crestelo Víeitez, Esther del Corral Beamount, Jesús Díez Manglano, Isabel Fiteni Mera, María del Mar García Andreu, Martín Geriço Aseguinolaza, Cristina Gallego Lezaun, Claudia Josa Laorden, Raúl Martínez Murgui, Marta Teresa Mata Sanz H. Reg. Univ. de Málaga: Mª Mar Ayala-Gutiérrez, Rosa Bernal López, José Bueno Fonseca, Verónica Andrea Buonaiuto, Luis Francisco Caballero Martínez, Lidia Cobos Palacios, Clara Costo Muriel, Francis de Windt, Ana Teresa Fernandez-Truchaud Christophel, Paula García Ocaña, Ricardo Gómez Huergas, Javier Gorospe García, José Antonio Hurtado Oliver, Sergio Jansen-Chaparro, María Dolores López-Carmona, Pablo López Quirantes, Almudena López Sampalo, Elizabeth Lorenzo-Hernández, Juan José Mancebo Sevilla, Jesica Martín Carmona, Luis Miguel Pérez-Belmonte, Iván Pérez de Pedro, Araceli Pineda-Cantarero, Carlos Romero Gómez, Michele Ricci, Jaime Sanz Cánovas. H. U. La Paz. Madrid: Jorge Álvarez Troncoso, Francisco Arnalich Fernández, Francisco Blanco Quintana, Carmen Busca Arenzana, Sergio Carrasco Molina, Aranzazu Castellano Candalija, Germán Daroca Bengoa, Alejandro de Gea Grela, Alicia de Lorenzo Hernández, Alejandro Díez Vidal, Car-
Martin Oterino, Leticia Moralejo Alonso, Sonia Peña Balbuena, María Luisa Pérez García, Ana Ramon Prados, Beatriz Rodríguez-Alonso, Ángela Romero Alegria, María Sanchez Ledesma, Rosa Juana Tejera Pérez. H. de Mataró. Barcelona: Raquel Aranega González, Ramon Boixeda, Javier Fernández Fernández, Carlos Lopera Mármol, Marta Parra Navarro, Ainhoa Rex Guzmán, Aleix Serrallonga Fustier C. H. U. de Ferrol (A Coruña): Hortsensia Alvarez Diaz, Tamara Dalama Lopez, Estefania Martul Pégo, Carmen Mella Pérez, Ana Pazos Ferro, Sabela Sánchez Trigo, Dolores Suarez Sambade, Maria Trigas Ferrin, Maria del Carmen Vázquez Friol, Laura Vilariño Maneiro. H. Público de Monforte de Lemos (Lugo): José López Castro, Manuel Lorenzo López Reboiro, Cristina Sardiña González H. General Defensa. Zaragoza: Anyuli Gracia Gutiérrez, Leticia Esther Royo Trallero H. Germans Trias i Pujol. Badalona (Barcelona): Elia Fernández Pedregas, Gemma Lladós Bertran, Xoel Pena Pérez. H. do Salnes. Vilagarcía de Arousa (Pontevedra): Vanesa Alende Castro, Ana María Baz Lomba, Ruth Brea Aparicio, Marta Fernández Morales, Jesús Manuel Fernández Villar, María Teresa López Monteagudo, Cristina Pérez García, Lorena Rodriguez Ferreira, Diana Sande Llovo, María Begoña Valle Feijoo. H. U. HM Montepinice: José F. Varona Arche.

References
1. COVID-19 Map—Johns Hopkins Coronavirus Resource Center. Available online: https://coronavirus.jhu.edu/map.html (accessed on 10 February 2022).
2. Mackey, K.; Ayers, C.K.; Kondo, K.K.; Saha, S.; Advani, S.M.; Young, S.; Spencer, H.; Rusek, M.; Anderson, J.; Veazie, S.; et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review. Ann. Intern. Med. 2021, 174, 362–373. [CrossRef] [PubMed]
3. Acosta, A.M.; Garg, S.; Pham, H.; Whitaker, M.; Anglin, O.; O’Halloran, A.; Milucky, J.; Patel, K.; Taylor, C.; Wortham, J.; et al. Racial and Ethnic Disparities in Rates of COVID-19-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021. JAMA Netw. Open 2021, 4, e2130479. [CrossRef] [PubMed]
4. Buikema, A.R.; Buzincz, P.; Paudel, M.L.; Andrade, K.; Johnson, J.C.; Edmonds, Y.M.; Jham, S.K.; Chastek, B.; Raja, H.; Cao, F.; et al. Racial and ethnic disparity in clinical outcomes among patients with confirmed COVID-19 infection in a large US electronic health record database. EClinicalMedicine 2021, 39, 101075. [CrossRef] [PubMed]
5. Vahidy, E.S.; Nicolas, J.C.; Meeks, J.R.; Khan, O.; Pan, A.; Jones, S.L.; Masud, F.; Sostman, H.D.; Phillips, R.; Andrieni, J.D.; et al. Increased racial disparity in COVID-19 mortality: Analysis of a COVID-19 observational registry for a diverse US metropolitan population. BMJ Open 2020, 10, e039849. [CrossRef]
6. Carbonell, R.; Urgelés, S.; Rodriguez, A.; Bodí, M.; Martin-Loeches, I.; Solé-Violán, J.; Díaz, E.; Gómez, J.; Treffler, S.; Vallverdú, M.; et al. Mortality comparison between the first and second/third waves among 3795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. Lancet Reg. Health Eur. 2021, 11, 100243. [CrossRef] [PubMed]
7. Mukherjee, B.; Gu, T.; Mack, J.A.; Salvatore, M.; Prabhu Sankar, S.; Valley, T.S.; Singh, K.; Nallamothu, B.K.; Kheterpal, S.; Lisabeth, L.; et al. Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System. JAMA Netw. Open 2020, 3, e2025197. [CrossRef]
8. Betty, G.D.; Gaye, B.; Gale, C.; Hamer, M.; Lassale, C. Explaining ethnic disparities in COVID-19 mortality: Population-based, prospective cohort study. medRxiv 2021. [CrossRef]
9. Instituto Nacional de Estadística Resident Population by Date, Sex, Age Group and Country of Birth (Groups of Countries) (9689). Available online: https://www.ine.es/jaxiT3/Tabla.htm?t=9689&L=1 (accessed on 6 December 2021).
10. Otero-Rodríguez, S.; Moreno-Pérez, O.; Ramos, J.M.; García, M.; Boix, V.; Reus, S.; Torrus, D.; Chico-Sánchez, P.; Sánchez-Payá, J.; Aldana-Macias, F.; et al. Latin American Origin Is Not Associated with Worse Outcomes among Hospitalized Patients with COVID-19 in a Public Healthcare System. Microorganisms 2021, 9, 1772. [CrossRef]
11. Guijarro, C.; Pérez-Fernández, E.; González-Piñeiro, B.; Meléndez, V.; Goyanes, M.J.; Renilla, M.E.; Casas, M.L.; Sastre, I.; Velasco, M.; e investigadores COVID Alcorcón; et al. Differential risk for COVID-19 in the first wave of the disease among Spaniards and migrants from different areas of the world living in Spain. Rev. Clin. Esp. 2021, 221, 264–273. [CrossRef]
12. Norman, F.F.; Crespillo-Andújar, C.; Pérez-Molina, J.A.; Comeche, B.; Chamorro, S.; Monge-Maillo, B.; Moreno-Guillén, S.; López-Vélez, R.; Vizcarra, P.; Norman, E.; et al. COVID-19 and geographical area of origin. Clin. Microbiol. Infect. 2021, 27, 632.e1–632.e5. [CrossRef] [PubMed]
13. Castilla, J.; Guevara, M.; Miqueleiz, A.; Baigorria, F.; Ibero-Esparza, C.; Navascués, A.; Trobajo-Sanmartín, C.; Martínez-Baz, I.; Casado, I.; Burgui, C.; et al. Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. J. Clin. Med. 2021, 10, 2608. [CrossRef] [PubMed]
14. Valls Carbó, A.; González del Castillo, J.; Miró, O.; López-Ayala, P.; Jimenez, S.; Jacob, J.; Bibiano, C.; Martín-Sánchez, F.J. Increased severity in SARS-CoV-2 infection of minorities in Spain. Rev. Esp. Quimioter. 2021, 34, 664–667. [CrossRef]
15. Martín-Sánchez, F.J.; Valls Carbó, A.; Miró, Ò.; Llorens, P.; Jiménez, S.; Piñera, P.; Burillo-Putze, G.; Martín, A.; García-Lambrechts, J.E.; Jacob, J.; et al. Socio-Demographic Health Determinants Are Associated with Poor Prognosis in Spanish Patients Hospitalized with COVID-19. J. Gen. Intern. Med. 2021, 36, 3737–3742. [CrossRef][PubMed]

16. Aradhya, S.; Brandén, M.; Drefahl, S.; Obućina, O.; Andersson, G.; Rostila, M.; Mussino, E.; Juárez, S.P. Intermarriage and COVID-19 mortality among immigrants. A population-based cohort study from Sweden. BMJ Open 2021, 11, e048952. [CrossRef][PubMed]

17. Tartof, S.Y.; Qian, L.; Hong, V.; Wei, R.; Nadjafi, R.F.; Fischer, H.; Li, Z.; Shaw, S.F.; Caparosa, S.L.; Nau, C.L.; et al. Presenting characteristics and outcomes of patients in a cohort of hospitalized patients with COVID-19: Does the origin matter? Travel Med. Infect. Dis. 2021, 42, 102027. [CrossRef][PubMed]

18. Garcia, S.; Maria, A.; Abadía-Taira, B.; Durán, A.; Hernández-Quevedo, C.; Bernal-Delgado, E. Spain Health system review. Health Syst. Transit. 2010, 12, 1–294.

19. Casas-Royo, J.M.; Antón-Santos, J.M.; Millán-Nuñez-Cortés, J.; Lumberas-Bermejo, C.; Ramos-Rincón, J.M.; Roy-Vallejo, E.; Artero-Mora, A.; Arnalich-Fernández, F.; García-Bruñén, J.M.; Vargas-Nuñez, J.A.; et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. Rev. Clin. Esp. 2020, 220, 480–494. [CrossRef]

20. Ramos-Rincón, J.M.; Buonaiuto, V.; Ricci, M.; Martin-Carmona, J.; Paredes-Ruiz, D.; Calderon-Moreno, M.; Rubio-Rivas, M.; Beato-Pérez, J.L.; Arnalich-Fernández, E.; Monge-Monge, D.; et al. Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized With COVID-19 in Spain. J. Gerontol. A Biol. Sci. Med. Sci. 2021, 76, e28–e37. [CrossRef][PubMed]

21. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987, 40, 373–383. [CrossRef]

22. Pérez-Arellano, J.L.; Górgolas-Hernández-Mora, M.; Salvador, F.; Carranza-Rodríguez, C.; Ramírez-Olivencia, G.; Martín-Echeverría, E.; Rodríguez-Guardado, A.; Norman, F.; Velasco-Tirado, V.; Zuberbo-Sulbarria, Z.; et al. Executive summary of imported infectious diseases after returning from foreign travel: Consensus document of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC). Enferm. Infecc. Microbiol. Clin. 2018, 36, 187–193. [CrossRef][PubMed]

23. Ramos-Rincón, J.M. Imported diseases and travel medicine. Med. Clin. 2021, 156, 558–560. [CrossRef][PubMed]

24. Weng, C.H.; Saal, A.; Butt, W.W.W.; Chan, P.A. Characteristics and clinical outcomes of COVID-19 in Hispanic/Latino patients in a community setting: A retrospective cohort study. J. Med. Virol. 2021, 93, 115–117. [CrossRef][PubMed]

25. Williamson, E.J.; Walker, A.J.; Blaksharan, K.; Bacon, S.; Bates, C.; Morton-Carr, H.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Risk Factors for Severe COVID-19 with Respiratory Failure. J. Glob. Health 2021, 11, e024096. [CrossRef][PubMed]

26. McCarty, T.R.; Hathorn, K.E.; Redd, W.D.; Rodriguez, N.J.; Zhou, J.C.; Bazarbashi, A.N.; Njie, C.; Wong, D.; Trinh, Q.-D.; Shen, L.; et al. How Do Presenting Symptoms and Outcomes Differ by Race/Ethnicity Among Hospitalized Patients With Coronavirus Disease 2019 Infection? Experience in Massachusetts. Clin. Infect. Dis. 2021, 73, e1431–e1438. [CrossRef]

27. Patel, A.; Abdulla, A.; Ariyanayagam, D.; Killington, K.; Denny, S.J.; Mughal, N.; Hughes, S.; Goel, N.; Davies, G.W.; Moore, L.S.P.; et al. Investigating the association between ethnicity and health outcomes in SARS-CoV-2 in a London secondary care population. PLoS ONE 2020, 15, e0240960. [CrossRef]

28. Mude, W.; Ogouma, V.M.; Nyanhanda, T.; Mwanri, L.; Njie, C. Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis. J. Glob. Health 2021, 11, 05015. [CrossRef]

29. Kim, L.; Garg, S.; O’Halloran, A.; Whitaker, M.; Pham, H.; Anderson, E.J.; Armistead, I.; Bennett, N.M.; Billing, L.; Comos-Sabetti, K.; et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified Through the us Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin. Infect. Dis. 2021, 72, e206–e214. [CrossRef]

30. Ko, J.Y.; Danielson, M.L.; Town, M.; Derado, G.; Greenlund, K.J.; Kirley, P.D.; Alden, N.B.; Yousey-Hindes, K.; Anderson, E.J.; Ryan, P.A.; et al. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance and Behavioral Risk Factor Surveillance System. Clin. Infect. Dis. 2021, 72, E695–E703. [CrossRef]

31. Tartof, S.Y.; Qian, L.; Hong, V.; Wei, R.; Nadjafi, R.F.; Fischer, H.; Li, Z.; Shaw, S.F.; Caparosa, S.L.; Nau, C.L.; et al. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Ann. Intern. Med. 2020, 173, 773–781. [CrossRef][PubMed]

32. Tal, Y.; Adini, A.; Eran, A.; Adini, I. Racial disparity in COVID-19 mortality rates—A plausible explanation. Clin. Immunol. 2020, 217, 108481. [CrossRef]

33. Devaux, C.A.; Rolain, J.M.; Raoult, D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J. Microbiol. Immunol. Infect. 2020, 53, 425–435. [CrossRef]

34. Severe COVID-19 GWAS Group; Ellingham, D.; Degenhardt, F.; Bujanda, L.; Buti, M.; Albillos, A.; Invernizzi, P.; Fernández, J.; Prati, D.; Baselli, G.; et al. Genomewide Association Study of Severe COVID-19 with Respiratory Failure. N. Engl. J. Med. 2020, 383, 1522–1534. [CrossRef][PubMed]

35. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 2020, 28, 715–718. [CrossRef][PubMed]

36. Zeberg, H.; Pääbo, S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature 2020, 587, 610–612. [CrossRef][PubMed]
37. Mendy, A.; Wu, X.; Keller, J.L.; Fassler, C.S.; Apewokin, S.; Mersha, T.B.; Xie, C.; Pinney, S.M. Air pollution and the pandemic: Long-term PM 2.5 exposure and disease severity in COVID-19 patients. *Respirology* 2021, 26, 1181–1187. [CrossRef] [PubMed]

38. Islam, S.J.; Nayak, A.; Hu, Y.; Mehta, A.; Dieppa, K.; Almuwaqqat, Z.; Ko, Y.A.; Patel, S.A.; Goyal, A.; Sullivan, S.; et al. Temporal trends in the association of social vulnerability and race/ethnicity with county-level COVID-19 incidence and outcomes in the USA: An ecological analysis. *BMJ Open* 2021, 11, e048086. [CrossRef] [PubMed]

39. Onder, G.; Rezza, G.; Brusaferro, S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA-J. Am. Med. Assoc.* 2020, 323, 1775–1776. [CrossRef] [PubMed]

40. Barber, R.M.; Fullman, N.; Sorensen, R.J.D.; Bollyky, T.; McKee, M.; Nolte, E.; Abajobir, A.A.; Abate, K.H.; Abbafati, C.; Abbas, K.M.; et al. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: A novel analysis from the Global Burden of Disease Study 2015. *Lancet* 2017, 389, 231–266. [CrossRef]

41. BOE.es—BOE-A-2018-10752 Real Decreto-ley 7/2018, de 27 de Julio, Sobre el Acceso Universal al Sistema Nacional de Salud. Available online: https://www.boe.es/eli/es/rdl/2018/07/27/7 (accessed on 31 December 2021).

42. Carroll, J.F.; Chiapa, A.L.; Rodriguez, M.; Phelps, D.R.; Cardarelli, K.M.; Vishwanatha, J.K.; Bae, S.; Cardarelli, R. Visceral fat, waist circumference, and BMI: Impact of race/ethnicity. *Obesity* 2008, 16, 600–607. [CrossRef]

43. Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002, 287, 600–607. [CrossRef]

44. Toselli, S.; Gualdi-Russo, E.; Boulos, D.N.K.; Anwar, W.A.; Lakhoua, C.; Jaouadi, I.; Khyatti, M.; Hemminki, K. Prevalence of overweight and obesity in adults from North Africa. *Eur. J. Public Health* 2014, 24, 31–39. [CrossRef] [PubMed]

45. European Commission, Directorate-General for Justice and Consumers; Farkas, L. *Analysis and Comparative Review of Equality Data Collection Practices in the European Union; Data Collection in the Field of Ethnicity*; Publications Office: Brussels, Belgium, 2020.